Rep. Robert Bresnahan, Jr. Sells Pfizer Inc. (NYSE:PFE) Shares

Posted by Lauren Steadman on Apr 30th, 2025

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on April 28th, the Representative disclosed that they had sold between $15,001 and $50,000 in Pfizer stock on April 8th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of DexCom (NASDAQ:DXCM) on 4/8/2025.
Sold $1,001 – $15,000 in shares of Invesco (NYSE:IVZ) on 4/8/2025.
Sold $1,001 – $15,000 in shares of Generac (NYSE:GNRC) on 4/8/2025.
Sold $15,001 – $50,000 in shares of Occidental Petroleum (NYSE:OXY) on 4/8/2025.
Sold $1,001 – $15,000 in shares of QUALCOMM (NASDAQ:QCOM) on 4/8/2025.
Sold $1,001 – $15,000 in shares of Best Buy (NYSE:BBY) on 4/8/2025.
Sold $1,001 – $15,000 in shares of EOG Resources (NYSE:EOG) on 4/8/2025.
Sold $1,001 – $15,000 in shares of CSX (NASDAQ:CSX) on 4/8/2025.
Sold $1,001 – $15,000 in shares of Valero Energy (NYSE:VLO) on 4/8/2025.
Sold $15,001 – $50,000 in shares of Accenture (NYSE:ACN) on 4/8/2025.

Pfizer Stock Performance

Shares of PFE stock opened at $23.80 on Wednesday. The firm has a market cap of $134.98 billion, a price-to-earnings ratio of 16.88, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm’s 50-day simple moving average is $24.48 and its two-hundred day simple moving average is $25.86. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue was down 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.82 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.23%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio is 121.99%.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Nordea Investment Management AB grew its stake in shares of Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after purchasing an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI grew its stake in shares of Pfizer by 118.7% in the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock worth $7,820,000 after acquiring an additional 159,984 shares during the last quarter. Copley Financial Group Inc. purchased a new stake in shares of Pfizer in the third quarter worth $577,000. Mcdonald Partners LLC grew its stake in shares of Pfizer by 9.9% in the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock worth $2,926,000 after acquiring an additional 9,963 shares during the last quarter. Finally, Merit Financial Group LLC grew its stake in shares of Pfizer by 60.8% in the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock worth $3,395,000 after acquiring an additional 48,397 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on PFE shares. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. UBS Group lowered their price objective on Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 8th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective on the stock. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $29.57.

Get Our Latest Report on PFE

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Pfizer

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.